CLDX
$27.53-4.84%
Celldex Therapeutics Inc.Stock · HealthcareRussell 2000 0.09%Nasdaq Composite 0.008%Russell 3000 0.004%US Stock Market 0.004%
CLDX financial statements
The full income statement, balance sheet, and cash-flow statement for Celldex Therapeutics Inc. (CLDX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 66.3M2024-09 66.3M2024-12 66.4M2025-03 66.4M2025-06 66.4M2025-09 66.4M2025-12 66.6M2026-03 78.5M2026-06 78.5M+18.5% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
As-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 1.54M-78.0% | 7.02M+2.0% | 6.88M+192.0% | 2.36M-49.3% | 4.65M-37.3% | |
| Cost of revenue | 200K+0.0% | 200K-33.3% | 300K+200.0% | 100K+0.0% | 100K-50.0% | |
| Research & development | 245M+49.8% | 164M+38.6% | 118M+43.5% | 82.3M+54.3% | 53.3M+25.3% | |
| Selling, general & administrative | 43.8M+13.7% | 38.5M+24.7% | 30.9M+13.7% | 27.2M+32.7% | 20.5M+41.7% | |
| General & administrative | 43.8M+13.7% | 38.5M+24.7% | 30.9M+13.7% | 27.2M+32.7% | 20.5M+41.7% | |
| Operating income | -287M-47.3% | -195M-26.2% | -155M-34.1% | -115M-61.7% | -71.2M-12.5% | |
| Gain (loss) on equity securities | -19.4M-113.6% | 143M+77.2% | 80.4M-40.0% | 134M | — | |
| Pre-tax income | -259M-63.9% | -158M-11.6% | -141M-25.9% | -112M-58.8% | -70.7M-16.1% | |
| Income tax | 0.00 | 0.00 | 0.00 | — | -227K+80.5% | |
| -259M-63.9% | -158M-11.6% | -141M-25.9% | -112M-59.3% | -70.5M-18.0% | ||
| Net income to common | -259M-63.9% | -158M-11.6% | -141M-25.9% | -112M-59.3% | -70.5M-18.0% | |
| -$3.90-59.2% | -$2.45+16.1% | -$2.92-21.7% | -$2.40-46.3% | -$1.64+18.8% | ||
| EPS (basic) | -$3.90-59.2% | -$2.45+16.1% | -$2.92-21.7% | -$2.40-46.3% | -$1.64+18.8% | |
| Weighted-avg shares (basic) | 66.4M+3.1% | 64.4M+32.9% | 48.4M | — | — | |
| Weighted-avg shares (diluted) | 66.4M+3.1% | 64.4M+32.9% | 48.4M | — | — | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 535M-28.4% | 747M+73.1% | 432M+35.9% | 318M-22.7% | 411M+107.7% | ||
| Cash & equivalents | 28.9M+1.8% | 28.4M-18.6% | 34.8M+18.3% | 29.4M-24.8% | 39.1M-10.7% | |
| Short-term investments | 490M-29.7% | 697M+79.3% | 389M+41.1% | 276M-25.4% | 369M+145.1% | |
| Prepaid expenses | 14.1M-33.5% | 21.2M+287.4% | 5.47M-55.9% | 12.4M+412.8% | 2.42M+49.3% | |
| 583M-26.4% | 792M+70.2% | 466M+32.0% | 353M-20.7% | 445M+88.5% | ||
| Property, plant & equipment | 5.33M+22.7% | 4.35M+7.0% | 4.06M+8.4% | 3.75M+5.5% | 3.55M-6.9% | |
| Operating lease right-of-use | 2.44M-37.5% | 3.90M+51.3% | 2.58M-35.6% | 4.00M+34.7% | 2.97M-13.9% | |
| Intangible assets | 27.2M+0.0% | 27.2M+0.0% | 27.2M+0.0% | 27.2M+0.0% | 27.2M-11.4% | |
| Other non-current assets | 13.4M+37.0% | 9.75M+9009.3% | 107K+2.9% | 104K+0.0% | 104K+153.7% | |
| 51.0M+29.1% | 39.5M+26.9% | 31.1M+67.2% | 18.6M+12.6% | 16.5M+16.3% | ||
| Accounts payable | 1.18M-63.9% | 3.27M-6.6% | 3.49M+4.6% | 3.34M+172.0% | 1.23M+17.2% | |
| Accrued liabilities | 47.0M+39.0% | 33.8M+53.6% | 22.0M+71.6% | 12.8M+7.0% | 12.0M+41.9% | |
| Current lease liability | 1.55M+6.9% | 1.45M-10.0% | 1.61M+11.7% | 1.45M-17.2% | 1.75M+31.6% | |
| Other current liabilities | 1.23M+30.6% | 942K-76.4% | 3.99M+302.8% | 990K-36.3% | 1.55M-53.9% | |
| 55.8M+23.1% | 45.3M+24.4% | 36.5M+37.4% | 26.5M+5.4% | 25.2M-4.9% | ||
| Non-current lease liability | 784K-66.8% | 2.36M+154.4% | 928K-64.1% | 2.59M+99.7% | 1.30M-39.8% | |
| Operating lease liability (total) | 2.34M-38.7% | 3.81M+50.0% | 2.54M-37.0% | 4.03M+32.6% | 3.04M-12.6% | |
| Other non-current liabilities | 4.04M+16.4% | 3.47M-21.1% | 4.40M-17.4% | 5.33M-27.5% | 7.35M-27.3% | |
| 527M-29.4% | 747M+74.1% | 429M+31.6% | 326M-22.2% | 419M+100.4% | ||
| Preferred stock | — | — | — | 0.00 | 0.00 | |
| Common stock | 67.0K+1.5% | 66.0K+17.9% | 56.0K+19.1% | 47.0K+0.0% | 47.0K+17.5% | |
| Additional paid-in capital | 2.34B+1.7% | 2.30B+26.1% | 1.82B+15.3% | 1.58B+1.3% | 1.56B+22.0% | |
| Retained earnings | -1.81B-16.6% | -1.56B-11.3% | -1.40B-11.3% | -1.26B-9.8% | -1.14B-6.6% | |
| Accumulated other comprehensive income | 3.63M+9.4% | 3.31M+0.2% | 3.31M+162.5% | 1.26M-33.5% | 1.89M-26.8% | |
| Total liabilities & equity | 583M-26.4% | 792M+70.2% | 466M+32.0% | 353M-20.7% | 445M+88.5% | |
| Common shares issued | 66.5M+0.3% | 66.4M+18.8% | 55.9M+18.4% | 47.2M+1.0% | 46.7M+18.0% | |
| Common shares outstanding | 66.5M+0.3% | 66.4M+18.8% | 55.9M+18.4% | 47.2M+1.0% | 46.7M+18.0% | |
| Shares outstanding (cover) | 66.6M+0.3% | 66.4M+18.8% | 55.9M+18.4% | 47.2M+1.0% | 46.7M+18.0% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -211M-33.7% | -158M-47.1% | -107M-3.4% | -104M-70.3% | -60.9M-50.7% | ||
| Depreciation & amortization | 3.38M+6.4% | 3.18M+5.6% | 3.01M+3.9% | 2.90M-5.6% | 3.07M-21.9% | |
| Share-based compensation | 36.2M+5.8% | 34.2M+43.3% | 23.9M+53.0% | 15.6M+74.4% | 8.95M+128.7% | |
| 209M+172.1% | -290M-174.3% | -106M-217.6% | 89.9M+141.6% | -216M-120.1% | ||
| Capital expenditure | 2.71M+41.4% | 1.92M+5.6% | 1.82M-0.5% | 1.83M+46.4% | 1.25M-19.5% | |
| Free cash flow | -214M-33.8% | -160M-46.4% | -109M-3.4% | -106M-69.8% | -62.2M-48.2% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 2.39M-99.5% | 441M+102.1% | 218M+5259.6% | 4.08M-98.5% | 272M+59.1% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00-100.0% | 432M+99.9% | 216M | 0.00-100.0% | 270M+58.0% | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net change in cash | 515K+108.0% | -6.46M-219.9% | 5.38M+155.4% | -9.71M-107.0% | -4.69M-114.4% | |
| Income taxes paid | 0.00 | 0.00 | 0.00 | — | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 1.81B+7.8% | 1.68B-10.5% | 1.87B-10.7% | 2.10B+16.2% | 1.81B+160.2% | |
| P/S | 1170.2×+389.7% | 239.0×-44.4% | 429.4×-77.9% | 1947.3×+401.5% | 388.3×+315.0% | |
| P/B | 3.4×+52.7% | 2.2×-70.4% | 7.6×+25.0% | 6.1×+41.2% | 4.3×+29.9% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: CLDX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all CLDX filings on SEC EDGAR → Not investment advice.